- Home
- IMCR vs BEAM Comparison
IMCR vs BEAM Comparison
Compare IMCR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BEAM
- Stock Information
- Founded
- IMCR 2008
- BEAM 2017
- Country
- IMCR United Kingdom
- BEAM United States
- Employees
- IMCR N/A
- BEAM N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMCR Health Care
- BEAM Health Care
- Exchange
- IMCR Nasdaq
- BEAM Nasdaq
- Market Cap
- IMCR 1.7B
- BEAM 1.7B
- IPO Year
- IMCR 2021
- BEAM 2020
- Fundamental
- Price
- IMCR $34.26
- BEAM $25.23
- Analyst Decision
- IMCR Buy
- BEAM Strong Buy
- Analyst Count
- IMCR 9
- BEAM 10
- Target Price
- IMCR $57.00
- BEAM $49.78
- AVG Volume (30 Days)
- IMCR 287.1K
- BEAM 2.4M
- Earning Date
- IMCR 11-05-2025
- BEAM 11-04-2025
- Dividend Yield
- IMCR N/A
- BEAM N/A
- EPS Growth
- IMCR N/A
- BEAM N/A
- EPS
- IMCR N/A
- BEAM N/A
- Revenue
- IMCR $356,145,000.00
- BEAM $60,272,000.00
- Revenue This Year
- IMCR $29.71
- BEAM N/A
- Revenue Next Year
- IMCR $11.27
- BEAM $18.95
- P/E Ratio
- IMCR N/A
- BEAM N/A
- Revenue Growth
- IMCR 26.78
- BEAM N/A
- 52 Week Low
- IMCR $23.15
- BEAM $13.53
- 52 Week High
- IMCR $39.33
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- IMCR 49.34
- BEAM 65.07
- Support Level
- IMCR $33.92
- BEAM $22.53
- Resistance Level
- IMCR $37.00
- BEAM $26.48
- Average True Range (ATR)
- IMCR 1.45
- BEAM 1.32
- MACD
- IMCR -0.06
- BEAM 0.07
- Stochastic Oscillator
- IMCR 39.78
- BEAM 68.35
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.